IQ-AI Limited KFDA Clearance for StoneChecker Software (2389A)
20 Enero 2020 - 01:00AM
UK Regulatory
TIDMIQAI
RNS Number : 2389A
IQ-AI Limited
20 January 2020
IQ-AI Ltd
("IQ-AI" or the "Company")
IQ-AI Announce Korean FDA Clearance to Market for StoneChecker
Software, and GMP certification for Imaging Biometrics, and the
appointment of Dr Balaji Ganeshan as consultant
IQ-AI has received notification that the Korean FDA (KFDA) has
cleared StoneChecker Software for marketing in the Republic of
Korea, a key market for high-tech medical imaging hardware and
software. In addition, Imaging Biometrics (IB) has received GMP
certification.
Trevor Brown, Chief Executive of IQ-AI commented, "We are
delighted that StoneChecker Software has received KFDA approval for
marketing in the Republic of Korea, our Korean distributor's
marketing plans can now be fully implemented. It also gives me
great pleasure to welcome back Dr Balaji Ganeshan to the team. Dr
Ganeshan, an exceptionally innovative medical imaging entrepreneur
and scientist, has invaluable expertise and ideas in a number of
key technologies relevant to the Company. He will be working as a
consultant for IB."
Dr Ganeshan, who was previously a director of StoneChecker
Software, holds the position of Senior Research Associate at the
Institute of Nuclear Medicine at University College London and is a
prolific academic scientist in the area of medical image
analysis.
Dr. Balaji Ganeshan commented, "I very much look forward to
working alongside Trevor Brown again, and also the team at IB, on
all the technologies that IQ-AI have access to."
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Michael Schmainda
Tel: 020 7469 0930
----------------------------------------------------------
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
----------------------------------------------------------
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker(R) and Imaging
Biometrics(R), is focused on advanced and state of the art medical
software and services. Imaging Biometrics develops and provides
visualization and analytical solutions that enable clinicians to
better diagnose and treat diseases with greater confidence. Through
close collaboration with researchers and clinicians, sophisticated
advancements are translated into platform-independent software
plug-ins which can extend the base functionality of workstations,
imaging systems, PACS, or medical viewers. By design, IB's advanced
visualization software seamlessly integrates into routine
workflows. Please visit www.imagingbiometrics.com for further
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
STRSFFFAUESSEEF
(END) Dow Jones Newswires
January 20, 2020 02:00 ET (07:00 GMT)
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Iq-ai (LSE:IQAI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024